Beta-block  ||| S:0 E:11 ||| JJ
the  ||| S:11 E:15 ||| DT
septic  ||| S:15 E:22 ||| JJ
heart  ||| S:22 E:28 ||| NN
Cardiac  ||| S:28 E:36 ||| NNP
depression  ||| S:36 E:47 ||| NN
is  ||| S:47 E:50 ||| VBZ
a  ||| S:50 E:52 ||| DT
well-described  ||| S:52 E:67 ||| JJ
manifestation  ||| S:67 E:81 ||| NN
of  ||| S:81 E:84 ||| IN
the  ||| S:84 E:88 ||| DT
sepsis  ||| S:88 E:95 ||| JJ
syndrome ||| S:95 E:103 ||| NN
.  ||| S:103 E:105 ||| .
An  ||| S:105 E:108 ||| DT
important  ||| S:108 E:118 ||| JJ
underlying  ||| S:118 E:129 ||| JJ
mechanism  ||| S:129 E:139 ||| NN
is  ||| S:139 E:142 ||| VBZ
the  ||| S:142 E:146 ||| DT
attenuation  ||| S:146 E:158 ||| NN
of  ||| S:158 E:161 ||| IN
the  ||| S:161 E:165 ||| DT
adrenergic  ||| S:165 E:176 ||| JJ
response  ||| S:176 E:185 ||| NN
at  ||| S:185 E:188 ||| IN
the  ||| S:188 E:192 ||| DT
cardiomyocyte  ||| S:192 E:206 ||| JJ
level ||| S:206 E:211 ||| NN
.  ||| S:211 E:213 ||| .
By  ||| S:213 E:216 ||| IN
reducing  ||| S:216 E:225 ||| VBG
their  ||| S:225 E:231 ||| PRP$
cell-specific  ||| S:231 E:245 ||| JJ
function  ||| S:245 E:254 ||| NN
( ||| S:254 E:255 ||| -LRB-
contractility ||| S:255 E:268 ||| LS
) ||| S:268 E:269 ||| -RRB-
,  ||| S:269 E:271 ||| ,
the  ||| S:271 E:275 ||| DT
cardiomyocytes  ||| S:275 E:290 ||| NN
reduce  ||| S:290 E:297 ||| VB
their  ||| S:297 E:303 ||| PRP$
energy  ||| S:303 E:310 ||| NN
expenditure ||| S:310 E:321 ||| NN
.  ||| S:321 E:323 ||| .
Consequently ||| S:323 E:335 ||| RB
,  ||| S:335 E:337 ||| ,
the  ||| S:337 E:341 ||| DT
cardiac  ||| S:341 E:349 ||| JJ
myocytes  ||| S:349 E:358 ||| NNS
survive  ||| S:358 E:366 ||| VBP
in  ||| S:366 E:369 ||| IN
a  ||| S:369 E:371 ||| DT
hibernation-like  ||| S:371 E:388 ||| JJ
state  ||| S:388 E:394 ||| NN
as  ||| S:394 E:397 ||| IN
long  ||| S:397 E:402 ||| JJ
as  ||| S:402 E:405 ||| IN
intracellular  ||| S:405 E:419 ||| JJ
energy  ||| S:419 E:426 ||| NN
generation  ||| S:426 E:437 ||| NN
is  ||| S:437 E:440 ||| VBZ
limited ||| S:440 E:447 ||| VBN
.  ||| S:447 E:449 ||| .
The  ||| S:449 E:453 ||| DT
objective  ||| S:453 E:463 ||| NN
of  ||| S:463 E:466 ||| IN
this  ||| S:466 E:471 ||| DT
study  ||| S:471 E:477 ||| NN
was  ||| S:477 E:481 ||| VBD
to  ||| S:481 E:484 ||| TO
review  ||| S:484 E:491 ||| VB
β-blocker  ||| S:491 E:501 ||| JJ
therapy  ||| S:501 E:509 ||| NN
for  ||| S:509 E:513 ||| IN
the  ||| S:513 E:517 ||| DT
treatment  ||| S:517 E:527 ||| NN
of  ||| S:527 E:530 ||| IN
septic  ||| S:530 E:537 ||| JJ
patients ||| S:537 E:545 ||| NNS
.  ||| S:545 E:547 ||| .
MEDLINE  ||| S:547 E:555 ||| NNP
database ||| S:555 E:563 ||| NN
.  ||| S:563 E:565 ||| .
During  ||| S:565 E:572 ||| IN
established  ||| S:572 E:584 ||| JJ
sepsis  ||| S:584 E:591 ||| NN
with  ||| S:591 E:596 ||| IN
organ  ||| S:596 E:602 ||| JJ
failure ||| S:602 E:609 ||| NN
,  ||| S:609 E:611 ||| ,
external  ||| S:611 E:620 ||| JJ
adrenergic  ||| S:620 E:631 ||| JJ
stimulation  ||| S:631 E:643 ||| NN
of  ||| S:643 E:646 ||| IN
the  ||| S:646 E:650 ||| DT
heart  ||| S:650 E:656 ||| NN
must  ||| S:656 E:661 ||| MD
be  ||| S:661 E:664 ||| VB
kept  ||| S:664 E:669 ||| VBN
at  ||| S:669 E:672 ||| IN
a  ||| S:672 E:674 ||| DT
minimum ||| S:674 E:681 ||| NN
.  ||| S:681 E:683 ||| .
To  ||| S:683 E:686 ||| TO
blunt  ||| S:686 E:692 ||| VB
the  ||| S:692 E:696 ||| DT
adrenergic  ||| S:696 E:707 ||| JJ
response ||| S:707 E:715 ||| NN
,  ||| S:715 E:717 ||| ,
β-blockers  ||| S:717 E:728 ||| NNS
have  ||| S:728 E:733 ||| VBP
been  ||| S:733 E:738 ||| VBN
used  ||| S:738 E:743 ||| VBN
in  ||| S:743 E:746 ||| IN
several  ||| S:746 E:754 ||| JJ
preclinical  ||| S:754 E:766 ||| NN
and  ||| S:766 E:770 ||| CC
clinical  ||| S:770 E:779 ||| JJ
studies ||| S:779 E:786 ||| NNS
.  ||| S:786 E:788 ||| .
In  ||| S:788 E:791 ||| IN
septic  ||| S:791 E:798 ||| JJ
animals ||| S:798 E:805 ||| NNS
,  ||| S:805 E:807 ||| ,
β-blockers  ||| S:807 E:818 ||| JJ
reduced  ||| S:818 E:826 ||| JJ
heart  ||| S:826 E:832 ||| NN
rate ||| S:832 E:836 ||| NN
,  ||| S:836 E:838 ||| ,
whereas  ||| S:838 E:846 ||| IN
stroke  ||| S:846 E:853 ||| JJ
volume  ||| S:853 E:860 ||| NN
was  ||| S:860 E:864 ||| VBD
maintained ||| S:864 E:874 ||| VBN
.  ||| S:874 E:876 ||| .
Esmolol  ||| S:876 E:884 ||| NNP
in  ||| S:884 E:887 ||| IN
vivo  ||| S:887 E:892 ||| NN
prevented  ||| S:892 E:902 ||| VBD
the  ||| S:902 E:906 ||| DT
downregulation  ||| S:906 E:921 ||| NN
of  ||| S:921 E:924 ||| IN
adrenergic  ||| S:924 E:935 ||| JJ
pathways ||| S:935 E:943 ||| NN
,  ||| S:943 E:945 ||| ,
preserving  ||| S:945 E:956 ||| VBG
full  ||| S:956 E:961 ||| JJ
cardiac  ||| S:961 E:969 ||| FW
function  ||| S:969 E:978 ||| FW
ex  ||| S:978 E:981 ||| FW
vivo ||| S:981 E:985 ||| FW
.  ||| S:985 E:987 ||| .
In  ||| S:987 E:990 ||| IN
addition ||| S:990 E:998 ||| NN
,  ||| S:998 E:1000 ||| ,
β-blockers  ||| S:1000 E:1011 ||| NNP
reduced  ||| S:1011 E:1019 ||| VBD
the  ||| S:1019 E:1023 ||| DT
inflammatory  ||| S:1023 E:1036 ||| JJ
response  ||| S:1036 E:1045 ||| NN
and  ||| S:1045 E:1049 ||| CC
the  ||| S:1049 E:1053 ||| DT
degree  ||| S:1053 E:1060 ||| NN
of  ||| S:1060 E:1063 ||| IN
lung  ||| S:1063 E:1068 ||| NN
injury ||| S:1068 E:1074 ||| NN
.  ||| S:1074 E:1076 ||| .
Some  ||| S:1076 E:1081 ||| DT
animal  ||| S:1081 E:1088 ||| NN
studies  ||| S:1088 E:1096 ||| NNS
documented  ||| S:1096 E:1107 ||| VBN
survival  ||| S:1107 E:1116 ||| NN
benefits ||| S:1116 E:1124 ||| NNS
,  ||| S:1124 E:1126 ||| ,
particularly  ||| S:1126 E:1139 ||| RB
when  ||| S:1139 E:1144 ||| WRB
β-blockers  ||| S:1144 E:1155 ||| NNP
were  ||| S:1155 E:1160 ||| VBD
administered  ||| S:1160 E:1173 ||| VBN
before  ||| S:1173 E:1180 ||| IN
the  ||| S:1180 E:1184 ||| DT
septic  ||| S:1184 E:1191 ||| JJ
insult ||| S:1191 E:1197 ||| NN
.  ||| S:1197 E:1199 ||| .
In  ||| S:1199 E:1202 ||| IN
patients  ||| S:1202 E:1211 ||| NNS
with  ||| S:1211 E:1216 ||| IN
septic  ||| S:1216 E:1223 ||| JJ
shock ||| S:1223 E:1228 ||| NN
,  ||| S:1228 E:1230 ||| ,
blood  ||| S:1230 E:1236 ||| NN
pressure  ||| S:1236 E:1245 ||| NN
increased  ||| S:1245 E:1255 ||| VBN
and  ||| S:1255 E:1259 ||| CC
cardiac  ||| S:1259 E:1267 ||| JJ
indices  ||| S:1267 E:1275 ||| NNS
remained  ||| S:1275 E:1284 ||| VBD
stable  ||| S:1284 E:1291 ||| JJ
with  ||| S:1291 E:1296 ||| IN
metoprolol  ||| S:1296 E:1307 ||| JJ
administration ||| S:1307 E:1321 ||| NN
.  ||| S:1321 E:1323 ||| .
Preclinical  ||| S:1323 E:1335 ||| NNP
and  ||| S:1335 E:1339 ||| CC
clinical  ||| S:1339 E:1348 ||| JJ
studies  ||| S:1348 E:1356 ||| NNS
with  ||| S:1356 E:1361 ||| IN
β-1  ||| S:1361 E:1365 ||| CD
receptor  ||| S:1365 E:1374 ||| NN
blockers  ||| S:1374 E:1383 ||| NN
during  ||| S:1383 E:1390 ||| IN
sepsis  ||| S:1390 E:1397 ||| NNS
show  ||| S:1397 E:1402 ||| VBP
promising  ||| S:1402 E:1412 ||| VBG
results ||| S:1412 E:1419 ||| NNS
.  ||| S:1419 E:1421 ||| .
Future  ||| S:1421 E:1428 ||| JJ
studies  ||| S:1428 E:1436 ||| NNS
are  ||| S:1436 E:1440 ||| VBP
needed  ||| S:1440 E:1447 ||| VBN
to  ||| S:1447 E:1450 ||| TO
establish  ||| S:1450 E:1460 ||| VB
the  ||| S:1460 E:1464 ||| DT
optimal  ||| S:1464 E:1472 ||| JJ
dose  ||| S:1472 E:1477 ||| NN
and  ||| S:1477 E:1481 ||| CC
timing  ||| S:1481 E:1488 ||| NN
of  ||| S:1488 E:1491 ||| IN
its  ||| S:1491 E:1495 ||| PRP$
administration ||| S:1495 E:1509 ||| NN
.  ||| S:1509 E:1511 ||| .
